Kornimate/medical-research-clean huggingface dataset:
validity and reliability of the thai kasrp

Conditions: Pain

Summary: pain is a very common symptom. pain was found to be a major cause for visiting a doctor. it accounted for 40% of the primary care visits. pain is also the leading cause of emergency department visits. physicians have a significant role for assessment and management of various kinds of pain. knowledge and attitude of doctors (as well as other health care providers) affect their pain management. a survey study using the knowledge and attitudes survey regarding pain (kasrp) questionnaire performed in malaysia revealed that 41.7% of respondents had scores less than 60% regarding pain knowledge. it also revealed that male medical officers had better performance than female medical officers. anesthesiologist showed the highest mean score. authors of this study concluded that there is a lack of knowledge and attitude on assessment and management of pain. a similar survey study was performed in jordan to evaluate health care providers' knowledge and attitudes by using the kasrp. even doctors had more pain knowledge in comparison to nurses, both of them demonstrated a low level of knowledge and negative attitudes in terms of pain management. a survey study from iran showed that less than half of health care providers who volunteered to complete a study questionnaire had correct response. only 9.3% of them thought that they had received sufficient teaching regarding pain and its management.

the knowledge and attitudes survey regarding pain (kasrp) the knowledge and attitudes survey regarding pain (kasrp) 2014 is a 39-item questionnaire. it comprises of 22 true or false questions and 17 multiple choice questions. its purpose is to measure knowledge and attitudes of health care providers in regard to pain. it is principally useful as a pre- and post-test measure and can be utilized to rate learning outcomes following educational programs on pain. the kasrp tool was developed in 1987 and has been used extensively since then until present. it has been revised over several years to reflect changes in pain management practice. its content validity has been established by review of pain specialists. the content of the kasrp tool is derived from standards of pain management such as the american pain society (aps), the world health organization (who), and the national comprehensive cancer network pain guidelines. its construct validity has been established by comparing scores of nurses at various levels of expertise such as students, new graduates, oncology nurses, graduate students, and senior pain experts. the tool was identified as discriminating between levels of expertise. test-retest reliability was established (r \> 0.80) by repeat testing in a continuing education class of nursing staffs (n = 60). internal consistency reliability was established (alpha r \> 0.70) with items reflecting both knowledge and attitude domains.

Eligibility criteria:
inclusion criteria: * health care providers exclusion criteria: * none
c-arm cone beam ctp guided cerebrovascular interventions

Conditions: Acute Ischemic Stroke

Summary: the study objective for the phase 2 of this research is to demonstrate and confirm the substantial time savings that can be obtained using cone beam computed tomography (cb-ct) for both complete image acquisition and rapid image reconstruction in a direct to angio paradigm (one stop shop) for selected acute ischemic stroke (ais) patients.

phase 2 of this research is aimed at validating the feasibility and time savings of bringing selected acute ischemic stroke patients with suspected large vessel occlusion directly on hospital arrival to the angiography suite, avoiding the emergency room and conventional md-ct imaging. in order to make this phase of the study more robust and to reduce bias on image assessment we will prospectively randomize the patients in a 2:1 fashion to either direct to angio for cb-ct imaging or md-ct imaging in the emergency room. a total of 60 cb-ct subjects and 30 md-ct subjects will comprise this cohort. entrance criteria will be identical to those in phase 1, except the nihss must be greater than 8 which is clinically correlative with a likely large vessel occlusion and, since this is standard of care imaging for acute ischemic stroke, gfr will be removed as an exclusionary criteria. the phase 1 of this research was registered to nct03232151.

Eligibility criteria:
inclusion criteria: 1. patients with acute ischemic stroke presenting within 24 hours of onset 2. patients that present with a large artery occlusion 3. adults 18 years of age or older. 4. patients of childbearing potential must not be pregnant. 5. national institutes of health stroke scale (nihss) of \<8 6. no severe co-morbidities exclusion criteria: 1. patients that are pregnant 2. history of severe renal disease (e.g. stage 4-5) 3. history of renal transplant

Keywords: stroke
magnetic resonance imaging of gynecologic malignancies involving the vagina

Conditions: Vaginal Cancer

Summary: the goal of this clinical research study is to learn if a type of mri scan called diffusion weighted imaging (dwi) is accurate in checking the status of tumors. researchers also want to learn if dwi can predict how tumors will respond to radiation therapy.

if you agree to take part in this study, information will be collected from your medical record including your age, sex, and status of the disease. for the mri scans, you will receive a routine contrast drug by vein. contrast drugs are used by doctors in order to see mri images more clearly. a modified mri scan will performed right after your scheduled standard-of-care mri scan. this modified mri scan is the investigational scan. to complete the modified mri scan, you will need to stay in the mri scanner for about 8 extra minutes. it should take about 47 minutes total to complete both scans. the way that researchers program the mri machine and the order in which the images are taken is what is being modified for the investigational scan. these changes may help researchers capture better images. length of study: your participation on this study will be over after the modified mri scan is complete. this is an investigational study. the standard-of-care mri scan method is fda approved and commercially available for the diagnosis of several diseases. the modified mri scan method is being used in research only. up to 25 participants will be enrolled in this study. all will take part at md anderson.

Eligibility criteria:
inclusion criteria: 1. all patients who have gynecologic malignancies involving the middle third and the distal third of the vagina who will be receiving radiation therapy 2. patients who have gynecologic malignancies involving the upper, middle and/or lower third of the vagina or are undergoing pelvic exenteration. exclusion criteria: 1. pregnant patients 2. any implantable medical device that is not mri compatible (e.g. pacemakers, defibrillators, pain pumps or insulin pumps)

Keywords: vaginal cancer malignancies involving the vagina middle third and the distal third of the vagina pre and post radiation therapy diffusion weighted magnetic resonance imaging dwmr magnetic resonance imaging mri tumor involvement response to radiation therapy xrt
long-term follow-up (ltfu) study of participants in any iecure protocol using an investigational product (ip)

Conditions: Ornithine Transcarbamylase Deficiency; Ornithine Transcarbamylase Deficiency Disease; Urea Cycle Disorders, Inborn

Summary: this ltfu is being conducted to assess long-term safety and durability of response in participants dosed with ip in a parent protocol, and to collect longitudinal natural history in enrolled but not dosed participants who also participated in a parent protocol.

this is a 14.5 year ltfu protocol to assess long term safety and clinical response to ip as well as to capture natural disease history of participants not dosed with ip in a parent protocol. no ip is provided as part of this protocol. participants will remain on standard of care medication as indicated and prescribed by their physicians.

Eligibility criteria:
inclusion criteria: 1. enrolled in an iecure parent protocol and have either completed or discontinued that protocol 2. participant parent(s)/lar is willing and able to adhere to the protocol requirements. 3. consent was obtained by the participants parent(s)/lar (and participant assent, where applicable), prior to any study-related data being collected. exclusion criteria: 1. participants who enroll into an interventional drug or gene therapy clinical trial utilizing an ip other than the ip provided in the parent protocol will be excluded from this protocol.

Keywords: amino acid metabolism, inborn errors ammonia brain diseases brain diseases, metabolic brain diseases, metabolic, inborn central nervous system diseases genetic diseases, inborn genetic diseases, x-linked high ammonia hyperammonemia inborn inborn errors liver disease liver transplant metabolism metabolic diseases metabolism, inborn errors neonatal nervous system diseases nh4 ornithine ornithine transcarbamylase deficiency otc otc deficiency otcd transcarbamylase ucd urea cycle disorders long term follow up long-term follow-up ltfu
complex evar in inflammatory and infective abdominal and thoracoabdominal aortic aneurysms

Conditions: Inflammatory Abdominal Aortic Aneurysm; Aneurysm, Infected; Aneurysm, Mycotic; Abdominal Aortic Aneurysm; Thoracoabdominal Aortic Aneurysm

Summary: complex endovascular aortic repair in inflammatory and infective perivisceral abdominal aortic aneurysms and thoracoabdominal aortic aneurysms (cevarii) study is a collaborative international effort among vascular surgeons to establish a database on the global experience in the management of inaas and iaas. ethical approval for the study was obtained from the colorado multiple institutional review board (comirb) under protocol number 23-1533.

infective native and inflammatory aortic aneurysms (inaa \& iaa) are rare, morbid conditions with unique challenges. inaa \& iaa share clinical and imaging similarities but differ significantly in pathophysiology, management, and prognosis. open surgical repair of inaa \& iaa is technically challenging and associated with higher complications. complex endovascular aortic repair in inflammatory and infective perivisceral abdominal aortic aneurysms and thoracoabdominal aortic aneurysms (cevarii) study is a collaborative international consortium effort among vascular surgeons to establish a database on the global experience in the management of inaas and iaas. cevarii study is irb approved with the number 23-1533. knowledge gained will help generate consensus on how to best manage patients with inflammatory and infective aortic aneurysms involving the visceral and thoracoabdominal aorta.

Eligibility criteria:
inclusion criteria: patients aged ≥ 18 years old with a diagnosis of inflammatory abdominal aortic aneurysm (iaa) or infective native aortic aneurysms (inaa), who have undergone complex endovascular aortic repair (cevar) are eligible for inclusion in this study. exclusion criteria: * suboptimal documentation of clinical, laboratory, and imaging findings * presence of prosthetic material (endograft or open graft material) * prior open or endovascular aortic repair * findings suspicious of secondary aorto-enteric or -bronchial fistulas.

Keywords: infected mycotic inflammatory aortic aneurysm inaa iaa infective native complex endovascular aortic repair
decision-making impairments in ocd: an integrated behavioral economics model

Conditions: Obsessive-Compulsive Disorder

Summary: the investigators are examining whether conditions of ambiguity during decision-making may prime intolerance of uncertainty beliefs (i.e., difficulties coping with ambiguity, unpredictability, and the future) and lead to impaired performance when individuals with obsessive-compulsive disorder (ocd) are making uncertain decisions compared to non-psychiatric controls.

the primary aims of this study are to examine the extent to which individuals with ocd avoid decisions that involve ambiguity through the use of self-report and behavioral measures. specifically, the investigators will examine how individuals with ocd minimize risk at the expense of monetary profit under conditions of ambiguity (relative to risky but unambiguous options) compared to non-psychiatric controls utilizing a series of judgment and decision-making (jdm) tasks.

Eligibility criteria:
inclusion criteria: * adults (age 18+) * meet dsm-5 criteria for principal ocd (ocd group) or no current dsm-5 diagnosis (npc group). * sufficient fluency of english to understand study procedures and questionnaires * ability to provide informed consent. * comfortable and capable of using a computer to complete computer-based decision-making tasks. exclusion criteria: * color-blindness (which prevents completion of certain tasks) * acute psychosis, bipolar disorder, substance use disorder, or suicidality. all other diagnostic comorbidities will be permitted to foster the accrual of a clinically relevant sample. * serious neurological disorder or impairment (e.g., brain damage, blindness), attention deficit hyperactivity disorder (adhd), intellectual disability, or autism.

Keywords: ocd intolerance of uncertainty
a study of novel study interventions and combinations in participants with colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with colorectal cancer (crc).

this is a phase ii, platform, open-label, multi-drug, multicenter, global study. this is a modular study, that includes a master protocol and substudies. partcipants will be randomised to one of the following intervention groups: * volrustomig + folfiri + bevacizumab group (arm a) * folfiri + bevacizumab group (arm b) the substudy will evaluate the effects of volrustomig in combination with folfiri (irinotecan, 5-fu, and leucovorin) and bevacizumab versus folfiri and bevacizumab only in participants with mismatch-repair-proficient (pmmr)/microsatellite stable (mss) metastatic crc (mcrc) in the absence of liver metastases and who have not received previous systemic treatment for advanced or metastatic disease.

Eligibility criteria:
overall inclusion criteria: * histopathologically confirmed colorectal adenocarcinoma. * provision of ffpe tumor sample collected as per soc. * presence of measurable disease by recist 1.1 criteria. * ecog performance status of 0 or 1. * life expectancy ≥ 12 weeks at the time of screening. substudy inclusion criteria: * no radiological evidence of liver metastasis. * no prior systemic therapy for mcrc, except for neoadjuvant/adjuvant chemotherapy where, \> 6 months have elapsed between completion of therapy and documented date of diagnosis of recurrent or metastatic disease. * known pmmr/mss status (only pmmr/mss mcrc allowed). * adequate organ and bone marrow function * body weight \> 35 kg at screening and at randomization. * contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. overall exclusion criteria: * central nervous system metastases or spinal cord compression * known history of severe allergy to any monoclonal antibody or study intervention. * any unresolved toxicity ctcae grade ≥ 2 from a previous anticancer therapy. * history of another primary malignancy. substudy exclusion criteria: * potentially resectable disease with multidisciplinary plan for radical surgery. * active or prior documented autoimmune or inflammatory disorders or cardiac conditions. * participants with a prior history of hypertensive crisis or hypertensive encephalopathy or bleeding risks. * deep venous thrombosis, pulmonary embolism, arterial thrombosis, transient ischemic attack or cerebrovascular accident. * history of abdominal or tracheoesophageal fistula, gi perforation and/or fistulae, or intraabdominal abscess within 6 months prior to randomization. * prior exposure to immune mediated therapy.

Keywords: metastatic disease immunotherapy liver metastasis mismatch-repair-proficient antibody targeting colorectal cancer cantor
impact of timing of pd assessments on measures of platelet reactivity in patients undergoing pci treated with cangrelor

Conditions: Coronary Artery Disease

Summary: this study is assessing the impact of timing of pd assessments on measures of platelet reactivity in patients undergoing pci treated with cangrelor.

cangrelor is characterized by reversible binding to the p2y12 receptor and is promptly inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma half-life. consequently the timing at which pd assessments are performed after blood sample collection may impact measures of platelet reactivity in patients treated with cangrelor. we therefore hypothesize that measures of platelet inhibitory effects observed in cangrelor treated patients will reduce with time following blood sampling.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * cad patients (stable cad, nste-acs, or stemi) undergoing pci and treated with cangrelor per standard of care. * treated with aspirin prior to the pci procedure per standard of care exclusion criteria: * treatment with an oral p2y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within past 10 days * treatment with oral anticoagulation (vitamin k antagonist, dabigatran, apixaban, rivaroxiban) within past 3 days * treatment with a glycoprotein iib/iiia inhibitor during pci * fibrinolytics within 48 hours * known hemoglobin\<10 gm/dl * known platelet count \<80x106/ml * active bleeding or hemodynamic instability * known end stage renal disease on hemodialysis * known severe hepatic dysfunction
trial of terbutaline for the treatment of status asthmaticus in children

Conditions: Status Asthmaticus

Summary: although widely used for the treatment of pediatric status asthmaticus, intravenous terbutaline has potentially significant side effects; may not improve outcomes; and may increase intensive care unit (icu) length of stay. this study is designed to test the efficacy of intravenous terbutaline for the treatment of status asthmaticus by adding intravenous terbutaline or placebo to standard asthma treatment. the dose of terbutaline or placebo will be titrated according to severity of illness as quantified by a validated clinical asthma score. differences in outcomes between the study groups, such as length of stay, hospital costs, and lung function will be compared.


Eligibility criteria:
inclusion criteria: * admission to the connecticut children's medical center (ccmc) pediatric intensive care unit (picu) with a primary admission diagnosis of status asthmaticus * modified pulmonary index score (mpis) of greater than or equal to 12 * age between birth and 18 years old exclusion criteria: * pre-existing cardiac or pulmonary disease * existing respiratory failure (requiring invasive or non-invasive mechanical ventilation) * hemodynamic or cardiovascular instability requiring inotropic support * the patient meets one of the criteria for withdrawal from the study due to patient safety concerns
minimally invasive interval debulking surgery in ovarian neoplasm: a feasibility study

Conditions: Stage IV Ovarian Carcinoma; Effects of Chemotherapy; Peritoneal Cavity Cancer

Summary: phase ii multicentric study

the aim of this prospective phase ii multicentric study is to assess feasibility and early complications rate of "total laparoscopic/robotic" interval debulking surgery in patients with a clinical complete/partial response to neoadjuvant chemotherapy for advanced ovarian cancer.

Eligibility criteria:
inclusion criteria: * age \>18 years, * advanced ovarian cancer submitted to neoadjuvant chemotherapy, * clinical or serological complete/partial response (recist; gcig), * ps ≤ 2 (ecog), * informed consent exclusion criteria: * borderline and non-epithelial ovarian tumors, * stable/progressive disease, * asa 3-4, * severe cardiopulmonary disease, * bmi \> 40

Keywords: ovarian cancer laparoscopy neoadjuvant chemotherapy robotic interval debulking surgery
drainage or pericardiocentesis (drop) alone for recurrent non-malignant pericardial effusions requiring intervention

Conditions: Pericardial Effusion

Summary: the drop study is a prospective, multi center, randomized, open-label trial to test the efficacy and safety of extended catheter pericardial drainage in patients with non-malignant pericardial effusions.

the trial will compared the efficacy and safety of pericardiocentesis alone compared with extended pericardial catheter drainage for the prevention of recurrent effusions in patients with non-malignant pericardial effusions requiring intervention.

Eligibility criteria:
inclusion criteria: * adult patients * pericardial effusion requiring pericardiocentesis * non-malignant etiology exclusion criteria: * known neoplastic etiology * known bacterial etiology

Keywords: pericardial effusion cardiac tamponade pericardiocentesis pericardial drainage prevention
evaluation of the effectiveness, compliance of ibuprofen in a sustained release form in the treatment of egyptian osteoarthritic patients

Conditions: Osteoarthritis; Pain; Morning Stiffness

Summary: this is a prospective, multi-center, post-marketing observational study to evaluate the effectiveness and compliance of ibuprofen in a sustained release form in the treatment of egyptian osteoarthritic patients.

this was a prospective, longitudinal, multicenter observational study conducted in a clinical practice setting where the study product was used in osteoarthritis patients as indicated in the approved package insert; the dosing regimen of brufen retard is 2 tablets as a single dose once daily.

Eligibility criteria:
inclusion criteria: * patients seeking treatment for osteoarthritis and there are clinical or radiological evidence of the disease, * male or female, age ≥ 18 * designated to treatment with ibuprofen in a sustained release form (brufen retard) according to the best criterion of the physician and if he decides to treat the patient according to labeled indication and dose for 4 weeks. * patients who have given their written informed consent to participate in the study * patients who are currently taking non steroidal anti inflammatory drugs (nsaids), should complete an initial washout phase 10 days depending on the half life of the drug taken exclusion criteria: * contraindications as described in company core data sheet (ccds) and specifically * patients with active peptic ulcer * patients who have presented reactions of hypersensitivity (asthma , rhinitis or urticaria ) with ibuprofen or other anti-inflammatory non steroids * patients with active cardiovascular disease and those taking aspirin/warfarin for prophylaxis for myocardial infarction (mi) or stroke * patients with moderate to severe renal diseases * patients with moderate to severe hepatic disease * patients with crohn's disease * patients included currently in another study * women of childbearing potential must not be pregnant * any patients the investigators consider ineligible for this study

Keywords: osteoarthritis pain morning stiffness